Vestis Corporation enters the post-earnings window having just delivered its most consequential session in over a year. Q2 adj. EPS of $0.16 doubled consensus of $0.08. Revenue of $659.4M edged past estimates. The stock jumped 29% in a single day — and the ripple effects are still playing out across the analyst community and the short book.
The earnings reaction squeezed an already-retreating short base. Short interest had been declining steadily since early April, when roughly 10.2 million shares were short — around 7.7% of the float. By May 12 that figure had fallen to 8.8 million shares, or 6.7% of float. The week's move alone trimmed the short position by nearly 9%. The ORTEX short score has tracked that easing too, dropping from 56.2 a week ago to 52.9 on Tuesday — still in neutral territory but clearly losing its bearish edge. Borrow conditions reinforce the message: cost to borrow remains negligible near 0.43%, and availability is loose, with lending pool utilization at just 7.3%, well off its 52-week high of 36.4%. There is no sign of borrow pressure, and nothing in the lending market suggests short sellers are scrambling.
Options positioning has moved toward a more neutral-to-bullish tilt. The put/call ratio eased to 0.93 on Tuesday, down from above 1.03 for most of the prior two weeks. That 20-day average PCR near 0.97 had been tilted defensively — and the post-earnings session saw it finally crack below the mean. Notably, earlier in the year the PCR briefly touched a 52-week low of 0.026, implying at some point there was strong call-side interest. The current reading suggests options traders are neither running for the exits nor aggressively positioned for continuation.
The analyst reaction has been swift and pointed. William Blair upgraded VSTS to Outperform on May 13 — the most unambiguous positive signal of the day. Baird lifted its target to $14 from $10 while holding Neutral, and Stifel raised its target to $11 from $8.50 on a maintained Hold. The moves are meaningful in context: the current mean price target of $8.87 is likely to shift materially once updated estimates are incorporated — Baird's new $14 target already sits well above it, suggesting the consensus is in flux. Goldman Sachs, which downgraded to Sell in January with a $5.30 target, has not yet updated its view; that position, if maintained, would sit as the clearest remaining bear case on the Street. EV/EBITDA at roughly 9.6x is up about one turn over the past 30 days, reflecting the price move. With confirmed FY2026 sales guidance of $2.68–$2.74 billion against an estimate of $2.65 billion, the company has given the bulls something concrete to build on.
The institutional structure adds an interesting layer. Corvex Management — the activist shop run by Keith Meister — holds roughly 15% of shares. Corvex and Meister's personal holding together amount to approximately 30% of the company combined. That concentrated, activist-aligned ownership is a notable feature: Corvex was a buyer in December 2025 at prices around $6.80, and the CEO James Barber also bought shares at those same levels. Both are now sitting on substantial unrealised gains. The degree of insider alignment was already high; it now has a catalyst behind it.
What to watch next: whether the Goldman Sachs Sell rating is revised in the coming days will define the clearest remaining divergence on VSTS, and whether short sellers continue to reduce positions as the stock tests the $12 level will determine if the post-earnings reset becomes more durable.
See the live data behind this article on ORTEX.
Open VSTS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
